1 - 170 of 170
Title Published in Access level OA Policy Year Views Downloads
Interleukin-18 binding protein deficiency results in gut microbiota dysbiosis and aggravated diet-induced MASH in miceJHEP reports
accessLevelPublic
2026 29 14
Diabétologie : ce qui a changé en 2025Revue médicale suisse
accessLevelRestricted
2026 9 0
Autoimmunity in MASLD : Focus on autoantibodies, anti‐apolipoprotein A1 IgG and G protein‐coupled receptorsEuropean journal of clinical investigation
accessLevelPublic
2025 73 247
Prise en charge de la dyslipidémie diabétiqueRevue médicale suisse
accessLevelRestricted
2025 6 0
Autoantibodies against apolipoprotein A-1 and cadmium : possible links tocardiovascular and liver diseases across multiple modelsESC (European Society of Cardiology) Congress 2025
2025 9 0
Autoantibodies against apolipoprotein A-1 and cadmium : Possible links tocardiovascular and liver diseases across multiple models93rd EAS (European Atherosclerosis Society) Congress
2025 10 0
Modulation of STAT6 signaling for hepatoprotectionFrontiers in pharmacology
accessLevelPublic
2025 1 8
Analogues du GLP-1 dans le traitement du diabète de type 2 et de l’obésité : la panacée ?Revue médicale suisse
accessLevelRestricted
2025 6 0
Multi-omics correlates of insulin resistance and circadian parameters mapped directly from human serumEuropean journal of neuroscience
accessLevelPublic
2024 84 162
Alterations of lipid homeostasis in morbid obese patients are partly reversed by bariatric surgeryiScience
accessLevelPublic
2024 87 68
S100A9 exerts insulin-independent antidiabetic and anti-inflammatory effectsScience advances
accessLevelPublic
2024 343 153
Linking antibody against apolipoprotein A-1 to nonalcoholic steatohepatitis in mice92nd EAS (European Atherosclerosis Society) Congress
2024 6 0
Corticosteroid therapy in older adults with cancer : Expert recommendations from a task force of the International Society of Geriatric OncologyJournal of geriatric oncology
accessLevelRestricted
2024 36 0
Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associatedsteatohepatitis in miceESC (Europan Society of Cardiology) Congress 2024
2024 4 0
Geospatial clustering of auto-antibodies against apolipoprotein A-1, heavy metals,cardiovascular and liver diseases in the general populationESC (Europan Society of Cardiology) Congress 2024
2024 10 0
Diabétologie : ce qui a changé en 2023Revue médicale suisse
accessLevelRestricted
2024 109 5
Lysophosphatidylinositols Are Upregulated After Human β-Cell Loss and Potentiate Insulin ReleaseDiabetes
accessLevelRestricted
2024 366 3
N ADPH oxidases in healthy white adipose tissue and in obesity : function, regulation, and clinical implicationsObesity
accessLevelPublic
2024 105 84
Linking Antibodies Against Apolipoprotein A-1 to Metabolic Dysfunction-Associated Steatohepatitis in MiceInternational journal of molecular sciences
accessLevelPublic
2024 124 127
Gastroparésie diabétique et diabète de type 1Revue médicale suisse
accessLevelRestricted
2024 123 2
Langerhans Cell Histiocytosis of the Suprasellar Region : Diagnosis on Thyroid CytologyEuropean thyroid journal
accessLevelPublic
2024 119 164
Geospatial clustering of auto-antibodies against apolipoprotein A-1, heavy metals, cardiovascular and liver diseases in the general population92nd EAS (European Atherosclerosis Society) Congress
2024 7 0
Gynécologie-obstétrique. Prise en charge et dépistage du diabète gestationnel : ce qui a changé en 2023Revue médicale suisse
accessLevelRestricted
2024 211 2
Toutes nos différences…Revue médicale suisse
accessLevelRestricted
2024 70 2
Interprofessional diabetes and foot management in low-and middle-income countries or humanitarian crises contextsInternational Diabetes Federation (IDF) virtual congress
accessLevelPublic
2023 56 88
Pied diabétique : une prise en charge complexe et multidisciplinaireRevue médicale suisse
accessLevelPublic
2023 130 35
Nonalcoholic fatty liver disease in type 1 diabetes : where are we?Polskie Archiwum Medycyny Wewnętrznej
accessLevelPublic
2023 89 70
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetesDiabetes & metabolism
accessLevelPublic
2023 133 411
A global research priority agenda to advance public health responses to fatty liver diseaseJournal of hepatology
accessLevelPublic
2023 120 363
Diabétologie : ce qui a changé en 2022Revue médicale suisse
accessLevelPublic
2023 147 20
Role of Oxidative Stress and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 in Nonalcoholic Fatty Liver DiseaseInternational journal of molecular sciences
accessLevelPublic
2023 128 128
Circadian organization of lipid landscape is perturbed in type 2 diabetic patientsCell reports medicine
accessLevelPublic
2023 272 146
Stéatopathie non alcoolique (NAFLD) et diabète : le mauvais mariageRevue médicale suisse
accessLevelPublic
2023 130 46
Unnecessary thyroid surgery rate for suspicious nodule in the absence of molecular testingEuropean thyroid journal
accessLevelPublic
2023 211 320
Traitement du diabète de type 2 : et si nous revenions à l’essentiel ?Revue médicale suisse
accessLevelPublic
2023 93 21
A multi–society Delphi consensus statement on new fatty liver disease nomenclatureJournal of hepatology
accessLevelPublic
2023 135 1,186
The impact of transsphenoidal surgery on pituitary function in patients with non-functioning macroadenomasEndocrine
accessLevelPublic
2023 145 282
Neuropathie diabétique : mise au pointRevue médicale suisse
accessLevelPublic
2022 167 773
Effectiveness of Therapeutic Patient Education Interventions in Obesity and Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsNutrients
accessLevelPublic
2022 187 252
NAFLD: From Mechanisms to Therapeutic ApproachesBiomedicines
accessLevelPublic
2022 152 192
Allergie à l’insuline : comment faire ?Revue médicale suisse
accessLevelPublic
2022 141 268
Non-alcoholic fatty liver disease in type 1 diabetes: prevalence and pathophysiologyFrontiers in endocrinology
accessLevelPublic
2022 155 294
Diabète pancréatopriveRevue médicale suisse
accessLevelPublic
2022 537 165
Pheochromocytoma presented by Takotsubo, unmasked by accumulation of paroxetine, in a cytochrome poor metabolizer patient: A case reportThérapie
accessLevelRestricted
2022 366 1
Interleukin-18 in metabolism: from mice physiology to human diseasesFrontiers in endocrinology
accessLevelPublic
2022 182 356
Canakinumab in patients with COVID-19 and type 2 diabetes – a multicentre, randomised, double-blind, placebo-controlled trialEClinicalMedicine
accessLevelPublic
2022 132 116
Sex-specific modulation of circulating growth differentiation factor-15 in patients with type 2 diabetes and/or obesityEndocrine connections
accessLevelPublic
2022 234 167
(650) Efficacy of therapeutic patient education interventions in metabolic disorders: a systematic review and meta-analysis58th EASD Annual Meeting of the European Association for the Study of Diabetes
2022 247 7
Circulating 1,5-anhydroglucitol as a biomarker of ß-cell mass independent of a diabetes phenotype in human subjectsThe Journal of clinical endocrinology and metabolism
accessLevelRestricted
2022 418 2
Moderate to Severe Soft Tissue Diabetic Foot Infections: A Randomized, Controlled, Pilot Trial of Post-debridement Antibiotic Treatment for 10 versus 20 daysAnnals of surgery
accessLevelPublic
2022 258 374
NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic OutlookAntioxidants
accessLevelPublic
2022 282 505
Dernières recommandations européennes sur les dyslipidémiesRevue médicale suisse
accessLevelPublic
2022 390 974
Hepatic non-parenchymal S100A9-TLR4-mTORC1 axis normalizes diabetic ketogenesisNature communications
accessLevelPublic
2022 380 125
Diabète : la pandémie comme révélateur de nos succès/nos faillesRevue médicale suisse
accessLevelPublic
2022 53 32
DiabétologieRevue médicale suisse
accessLevelPublic
2022 92 63
Hépatopathie et diabète de type 2Leading Opinions. Médecine Interne
accessLevelRestricted
2022 121 0
Tratamiento podológico del pie diabéticoEncyclopédie médico-chirurgicale. Podología
accessLevelRestricted
2022 120 0
Systematic Review and Meta-Analysis of the Usefulness of Epicardial Fat Thickness as a Non-Invasive Marker of the Presence and Severity of Nonalcoholic Fatty Liver DiseaseBiomedicines
accessLevelPublic
2022 156 122
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetesCardiovascular diabetology
accessLevelPublic
2022 112 305
Prise en charge podologique du pied diabétiqueEncyclopédie médico-chirurgicale. Podologie
accessLevelRestricted
2022 141 0
Growth differentiation factor-15 prevents glucotoxicity and connexin-36 downregulation in pancreatic beta-cellsMolecular and cellular endocrinology
accessLevelPublic
2022 105 153
Le diabète : une pandémie oubliée ?Revue médicale suisse
accessLevelPublic
2021 125 265
Inhibiteurs du SGLT2 : que des bénéfices?Revue médicale suisse
accessLevelPublic
2021 380 330
Is routine measurement of the serum C-reactive protein level helpful during antibiotic therapy for diabetic foot infection?Diabetes, Obesity and Metabolism
accessLevelRestricted
2021 189 0
Diabète de type MODY : une entité souvent méconnueRevue médicale suisse
accessLevelPublic
2021 179 212
Ether lipids, sphingolipids and toxic 1-deoxyceramides as hallmarks for lean and obese type 2 diabetic patientsActa Physiologica
accessLevelRestricted
2021 399 3
DiabétologieRevue médicale suisse
accessLevelRestricted
2021 204 2
Pathophysiology of NASH in endocrine diseasesEndocrine Connections
accessLevelPublic
2021 227 240
Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLDInternational journal of molecular sciences
accessLevelPublic
2021 154 260
DiabétologieRevue médicale suisse
accessLevelRestricted
2020 243 2
Diabète: et si on se mettait à la place du patient?Revue médicale suisse
accessLevelRestricted
2020 246 0
Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world settingDiabetes, Obesity and Metabolism
accessLevelPublic
2020 487 340
Thirteen-year trends in the prevalence of diabetes according to socioeconomic condition and cardiovascular risk factors in a swiss populationBMJ Open Diabetes Res Care
accessLevelPublic
2020 338 191
Real-World Effectiveness of Insulin Glargine 300 Initiation in SwitzerlandDiabetes, Metabolic Syndrome and Obesity
accessLevelPublic
2020 301 203
La NASH: une complication moins connue mais importante du diabèteRevue médicale suisse
accessLevelRestricted
2020 359 0
The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient dietTranslational Research
accessLevelPublic
2020 563 315
Quelle place pour les inhibiteurs de la DPP-4 en 2020?Revue médicale suisse
accessLevelRestricted
2020 550 0
Ulcère du pied chez un patient avec un diabète : quelle prise en charge médico-chirurgicale ?Revue médicale suisse
accessLevelRestricted
2020 333 1
Extremely high-dose insulin requirement in a diabetic patient with COVID-19: a case reportBMC Endocrine Disorders
accessLevelPublic
2020 207 145
Diabète après transplantation rénale : mise au pointRevue médicale suisse
accessLevelRestricted
2020 356 4
Three versus six weeks of antibiotic therapy for diabetic foot osteomyelitis: A prospective, randomized, non-inferiority pilot trialClinical Infectious Diseases
accessLevelPublic
2020 345 962
Insuffisance rénale chronique et nouveaux traitements antidiabétiques : tour d'horizon en 2019Revue médicale suisse
accessLevelPublic
2019 675 282
Thirteen-year trends in the prevalence of diabetes in an urban region of Switzerland: a population-based studyDiabetic Medicine
accessLevelRestricted
2019 263 0
Salivary cortisol is not associated with incident insulin resistance or type 2 diabetes mellitusEndocrine Connections
accessLevelPublic
2019 321 117
Faut-il prescrire plus d'inhibiteurs SGLT-2 ?Revue médicale suisse
accessLevelPublic
2019 305 150
[News in diabetology 2018]Revue médicale suisse
accessLevelPublic
2019 274 95
Multi-technique comparison of atherogenic and MCD NASH models highlights changes in sphingolipid metabolismScientific Reports
accessLevelPublic
2019 471 131
Nonalcoholic fatty liver disease burdenSwiss Medical Weekly
accessLevelPublic
2019 314 229
Prise en charge de la dyslipidémie chez les patients avec un diabète de type 1Revue médicale suisse
accessLevelPublic
2018 519 64
DiabétologieRevue médicale suisse
accessLevelPublic
2018 417 62
Observance thérapeutique et empilage médicamenteuxRevue médicale suisse
accessLevelPublic
2018 368 187
Fibroblast Growth Factor 15/19 - From Basic Functions to Therapeutic PerspectivesEndocrine Reviews
accessLevelPublic
2018 499 245
Transition optimale hôpital-domicile d'un patient diabétique de type 2 : quelques outilsRevue médicale suisse
accessLevelPublic
2018 567 180
Consequences of the Adoption of the IADPSG versus Carpenter and Coustan Criteria to Diagnose Gestational Diabetes: A Before-After ComparisonExperimental and Clinical Endocrinology and Diabetes
accessLevelRestricted
2018 515 2
An Overview on Diabetic Foot Infections, including Issues Related to Associated Pain, Hyperglycemia and Limb IschemiaCurrent Pharmaceutical Design
accessLevelRestricted
2018 490 1
Diabète prégestationnel : une entité de plus en plus fréquenteRevue médicale suisse
accessLevelPublic
2018 508 203
Diabète de type 1, activité physique et nouvelles technologiesRevue médicale suisse
accessLevelPublic
2018 772 409
β-Klotho deficiency protects against obesity through a crosstalk between liver, microbiota, and brown adipose tissueJCI insight
accessLevelPublic
2017 586 293
Utilité de la mesure en continu de la glycémie chez les patients diabétiques de type 2Revue médicale suisse
accessLevelRestricted
2017 393 0
Treatment challenges in type 1 diabetes after roux-en-Y gastric bypassSwiss Medical Weekly
accessLevelPublic
2017 412 218
AMPK activation caused by reduced liver lactate metabolism protects against hepatic steatosis in MCT1 haploinsufficient miceMolecular Metabolism
accessLevelRestricted
2017 418 0
Diabète sucré secondaire à une endocrinopathie : quand y penser ?Revue médicale suisse
accessLevelPublic
2017 549 1,053
Diètes cétogènes : la solution miracle ?Revue médicale suisse
accessLevelPublic
2017 1,340 711
Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human StudiesNutrients
accessLevelRestricted
2017 468 0
Translational Aspects of Diet and Non-Alcoholic Fatty Liver DiseaseNutrients
accessLevelRestricted
2017 491 0
Traitement du diabète: quand faire appel au diabétologue?Revue médicale suisse
accessLevelPublic
2017 372 215
Grip strength is not associated with incident type 2 diabetes mellitus in healthy adults: The CoLaus studyDiabetes Research and Clinical Practice
accessLevelRestricted
2017 472 0
DiabétologieRevue médicale suisse
accessLevelPublic
2017 408 121
GPR40 mediates potential positive effects of a saturated fatty acid enriched diet on boneMolecular Nutrition and Food Research
accessLevelPublic
2017 565 435
Effects of Antidiabetic Drugs on Gut Microbiota CompositionGenes
accessLevelRestricted
2017 441 0
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous PemphigoidDermatology
accessLevelRestricted
2017 426 0
Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examplesJournal of Immunological Methods
accessLevelRestricted
2017 398 1
Place des nouveaux antidiabétiques dans la population gériatriqueRevue médicale suisse
accessLevelRestricted
2016 419 1
Second-generation antisense oligonucleotides against β-catenin protect mice against diet-induced hepatic steatosis and hepatic and peripheral insulin resistanceFASEB Journal
accessLevelRestricted
2016 370 0
Fasting glycaemia to simplify screening for gestational diabetesBJOG: an International Journal of Obstetrics and Gynaecology
accessLevelRestricted
2016 593 1
Diabète gestationnel – quelles sont les approches non médicales ?Revue médicale suisse
accessLevelRestricted
2016 427 1
Comment faire pour prévenir le diabète de type 2 en Suisse?Revue médicale suisse
accessLevelRestricted
2016 421 2
Leptin as a Potential Regulator of FGF21Cellular physiology and biochemistry
accessLevelPublic
2016 628 253
Preserving of Postnatal Leptin Signaling in Obesity-Resistant Lou/C Rats following a Perinatal High-Fat DietPloS one
accessLevelPublic
2016 519 207
Sécurité cardiovasculaire des antidiabétiquesRevue médicale suisse
accessLevelRestricted
2016 428 0
DiabétologieRevue médicale suisse
accessLevelRestricted
2016 374 0
Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell ProtectionArteriosclerosis, Thrombosis, and Vascular Biology
accessLevelRestricted
2016 620 1
Low birth weight leads to obesity, diabetes and increased leptin levels in adults: the CoLaus studyCardiovascular Diabetology
accessLevelPublic
2016 536 243
Endocrine causes of nonalcoholic fatty liver diseaseWorld Journal of Gastroenterology
accessLevelRestricted
2015 486 0
Free Fatty Acids Impair FGF21 Action in HepG2 CellsCellular physiology and biochemistry
accessLevelPublic
2015 560 440
Metformine : nouvelles données pour une ancienne moléculeRevue médicale suisse
accessLevelRestricted
2015 449 2
Hepatic insulin resistance and increased hepatic glucose production in mice lacking Fgf21Journal of Endocrinology
accessLevelPublic
2015 823 406
Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?Molecular and Cellular Endocrinology
accessLevelPublic
2015 540 1,729
Classification du diabète : vers une hétérogénéité croissanteRevue médicale suisse
accessLevelRestricted
2015 396 0
Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose TissuePloS one
accessLevelPublic
2015 623 368
Le diabète en 2015 : en augmentation constante, mais avec une offre thérapeutique qui s'élargitRevue médicale suisse
accessLevelRestricted
2015 405 1
Prise en charge des facteurs de risque des maladies cardiovasculaires : qu'est-ce qui a vraiment changé en 15 ans ?Revue médicale suisse
accessLevelRestricted
2015 427 1
Edulcorants artificiels et diabète : faux amis ?Revue médicale suisse
accessLevelRestricted
2015 399 0
ApoA5 knockdown improves whole-body insulin sensitivity in high-fat-fed mice by reducing ectopic lipid contentJournal of Lipid Research
accessLevelRestricted
2015 470 0
Serum Vitamin D Concentrations Are Not Associated with Insulin Resistance in Swiss AdultsThe Journal of nutrition
accessLevelRestricted
2015 542 0
Transition en diabétologieRevue médicale suisse
accessLevelRestricted
2015 561 1
Diets and nonalcoholic fatty liver disease: The good and the badClinical nutrition
accessLevelRestricted
2014 677 1
Capsule Commentary on Patrick et al., Trends in Insulin Initiation and Treatment Intensification among Patients with Type 2 DiabetesJournal of general internal medicine
accessLevelRestricted
2014 596 1
Maladies hépatiques chroniques et diabèteRevue médicale suisse
accessLevelRestricted
2014 490 0
Traitement combiné d'insuline et d'analogue du GLP-1 : qu'en attendre ?Revue médicale suisse
accessLevelRestricted
2014 574 0
Ostα-/- mice exhibit altered expression of intestinal lipid absorption genes, resistance to age-related weight gain, and modestly improved insulin sensitivityAmerican Journal of Physiology. Gastrointestinal and Liver Physiology
accessLevelRestricted
2014 457 0
Muscle-specific activation of Ca(2+)/calmodulin-dependent protein kinase IV increases whole-body insulin action in miceDiabetologia
accessLevelRestricted
2014 503 0
Cellular mechanisms by which FGF21 improves insulin sensitivity in male miceEndocrinology
accessLevelRestricted
2013 764 0
CGI-58 knockdown sequesters diacylglycerols in lipid droplets/ER-preventing diacylglycerol-mediated hepatic insulin resistanceProceedings of the National Academy of Sciences
accessLevelRestricted
2013 505 0
Increased FGF21 plasma levels in humans with sepsis and SIRSEndocrine connections
accessLevelPublic
2013 637 295
Non-alcoholic fatty liver disease and insulin resistance: from bench to bedsideDiabetes & metabolism
accessLevelRestricted
2013 640 0
Enhanced fasting glucose turnover in mice with disrupted action of TUG protein in skeletal muscleJournal of Biological Chemistry
accessLevelRestricted
2013 507 0
Cellular mechanism by which estradiol protects female ovariectomized mice from high-fat diet-induced hepatic and muscle insulin resistanceEndocrinology
accessLevelRestricted
2013 465 0
Sport et diabète de type 1Revue médicale suisse
2013 674 0
Inflammation as a potential link between nonalcoholic fatty liver disease and insulin resistanceJournal of Endocrinology
accessLevelRestricted
2013 677 0
Thyroid hormone receptor-α gene knockout mice are protected from diet-induced hepatic insulin resistanceEndocrinology
accessLevelRestricted
2012 462 0
Development of insulin resistance in mice lacking PGC-1α in adipose tissuesProceedings of the National Academy of Sciences
accessLevelRestricted
2012 418 0
Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatic insulin resistance in conditional X-box-binding protein-1 (XBP1) knock-out miceJournal of Biological Chemistry
accessLevelRestricted
2012 438 0
Sommeil et diabèteRevue médicale suisse
accessLevelRestricted
2012 513 0
Diabète et stéatose hépatique non alcooliqueRevue médicale suisse
accessLevelRestricted
2012 632 0
Weight and mortality in adults with diabetesJAMA
accessLevelRestricted
2012 595 0
Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patientsActa Diabetologica
accessLevelRestricted
2012 439 0
Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in miceCell Metabolism
accessLevelRestricted
2011 456 0
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistanceHepatology
accessLevelRestricted
2011 446 1
Pregnancy does not accelerate corticotroph tumor progression in Nelson's syndromeJournal of Clinical Endocrinology and Metabolism
accessLevelRestricted
2011 480 0
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell functionDiabetes
accessLevelRestricted
2011 398 0
Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2Proceedings of the National Academy of Sciences
accessLevelRestricted
2011 505 0
Targeted expression of catalase to mitochondria prevents age-associated reductions in mitochondrial function and insulin resistanceCell Metabolism
accessLevelRestricted
2010 468 0
A high-fat, ketogenic diet causes hepatic insulin resistance in mice, despite increasing energy expenditure and preventing weight gainAmerican Journal of Physiology. Endocrinology and Metabolism
accessLevelRestricted
2010 445 0
Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individualsDiabetologia
accessLevelRestricted
2010 643 0
Myeloperoxidase and paraoxonase-1 in type 2 diabetic patientsNMCD. Nutrition Metabolism and Cardiovascular Diseases
accessLevelRestricted
2009 644 0
Mucocutaneous papillomatous papules in Cowden's syndromeClinical and experimental dermatology
accessLevelRestricted
2008 556 0
Assessment of hepatic glucose metabolism by indirect calorimetry in combination with a non-invasive technique using naturally enriched 13C glucose in healthy children and adolescentsHormone Research
accessLevelRestricted
2004 428 0
Metabolism of oral glucose in children born small for gestational age: evidence for an impaired whole body glucose oxidationMetabolism
accessLevelRestricted
2004 435 0
Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1The Journal of clinical endocrinology and metabolism
accessLevelRestricted
2003 638 0
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack